Scott Gottlieb Quotes


The overly engineered, overly regulated market that Obamacare created resulted in restrictive health care plans that provide little choice, and coverage that is far too costly for what the plans offer.


Citations

Gottlieb, Scott. "Obamacare's Premiums Are High Because Its Coverage Is Hollow." Forbes, 26 Oct. 2016.

Related Quotes

Cruz, a freshman senator with little political experience was elected with extensive Tea Party support in the Texas Republican primary where the Texas real contest is. He was so fanatical that when he could not get his fellow Republican Senators to shut down the government unless President Obama would not implement Obamacare which was enacted by the Congress and declared Constitutional by the Supreme Court. He then turned to the House of Representatives where there were a number of Tea Party Republicans. He helped lead a shutdown of the government, naively expecting the President to give up on his signature legislation. When he did not, the American public was angry at the Republicans for shutting down the government and costing the taxpayers over $80 billion dollars and inconveniencing many Americans. Finally, the House Speaker allowed an open vote and the Reasonable Republicans and the Democrats easily passed a continuing resolution to get the Government open again. However, another debt ceiling extension was coming up for a vote, and even after alienating most of his senior Republican Senate Colleagues and a large part of the American public, he gave this response to a journalist who asked if after the last fiasco, he would try to shut down the government again.


This statement, along with {633806}, was made by the President dozens of times. It is a quotation that had more influence on the political status of the nation than most others. Why Obama made such an absolute statement has been a mystery since, but the statement could not possibly have been literally true as long as the insurance companies had the right to cancel existing plans. When they did, they often laid the blame on the Obamacare rules, when the rules had grandfathered them in, but these were policies that the insurance companies saw as not sufficiently profitable in the new health insurance environment. The Republicans and many Democrats castigated Obama as millions of American lost their health insurance despite the President’s oft stated promise. Though not recognized at the time, the statement turned out to have been a huge gaff.


The Republicans were trying to repeal the first national health reform since Medicare. But the part was split over what they would replace it with. Many wanted to give the health insurers more power and profits, but other Republicans like Cruz did not want to see the helath insurance premiums increase. Ironically, most members of Congress at the time agreed with Cruz's focus on lowering or at least holding health insurance premiums steady, but this was vert hard to do without heavily regulating the insurance companies or adding a public insurance program to compete with the insurance companies or eliminate the rights of the individual states to regualte and control; insurance in their state. And no majority could be found for any of these.


Scott Gottlieb
Scott Gottlieb
  • Born: June 11, 1972
  • Nationality: American
  • Profession: Public Servant

Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.